AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 2498550
Drug: Short term
RxNorm normalized name: Short Term Oral Swab System KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Short term perioperative antibiotic (Group III)
Trial: 2498550
Drug: Conventional postoperative
RxNorm normalized name: ENSURE SURGERY PERIOPERATIVE KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional postoperative antibiotic regimens (Group I and II)
Trial: 2498550
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of penicillin and streptomycin (Group II)
Trial: 30660196
Drug: Yerba mate
RxNorm normalized name: yerba mate
DrugBank: Ilex paraguariensis leaf (DB14366)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yerba mate (YM) 1000 mL/day
Trial: 30660196
Drug: Green tea
RxNorm normalized name: Green Tea
DrugBank: Green tea leaf (DB14307)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Green tea (GT) 1000 mL/day
Trial: 30660196
Drug: Apple tea
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apple tea (AT, control group) 1000 mL/day
Trial: 28318997
Drug: Carotid endarterectomy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carotid endarterectomy (CEA) plus medical therapy
Trial: 30265333
Drug: Intrathecal morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal morphine (0.2 mg)
Trial: 24997747
Drug: Periarticular multimodal
RxNorm normalized name: camphor
DrugBank: Camphor (DB01744)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Periarticular multimodal drug injection
Trial: 21999886
Drug: Orodispersible escitalopram
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orodispersible escitalopram (2 × 10 mg and 1 × 20 mg)
Trial: 21999886
Drug: Conventional escitalopram
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional escitalopram (2 × 10 mg)
Trial: 17176206
Drug: Family treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Family treatments combined with pharmacotherapy
Trial: 8617070
Drug: Lower-intensity treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lower-intensity treatment (early mobilization and sustained maximal inflations)
Trial: 8617070
Drug: Higher-intensity treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher-intensity treatment (early mobilization, sustained maximal inflations, and single-handed percussions)
Trial: 4078729
Drug: 96 mg
RxNorm normalized name: camphor 96 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 96 mg of cocaine (intranasal pretreatment)
Trial: 4078729
Drug: 4 mg
RxNorm normalized name: lutein 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg of cocaine (intranasal pretreatment)
Trial: 4078729
Drug: Cocaine (i.v.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cocaine (i.v. injection after intranasal pretreatment)
Trial: 4078729
Drug: Repeated administration
RxNorm normalized name: eicosyl povidone (2 eicosyl branches-repeat)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repeated administration of cocaine
Trial: 31050950
Drug: Home PBM
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Home PBM treatments (n=4), administered three times per week for 12 weeks using the Vielight Neuro Gamma device.
Trial: 30587368
Drug: Anti-MAdCAM antibody
RxNorm normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Anti-MAdCAM antibody (PF-00547659)
Trial: 17654442
Drug: PKC-inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PKC-inhibitors
Trial: 17654442
Drug: PPAR-alpha and
RxNorm normalized name: One-Alpha
DrugBank: Alfacalcidol (DB01436)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PPAR-alpha and -gamma agonists
Trial: 17654442
Drug: Phosphodiesterase (PDE-5)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phosphodiesterase (PDE-5) inhibitors
Trial: 17654442
Drug: Statins plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Statins plus ACE inhibitors
Trial: 15206277
Drug: Intraoperative autoblood
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraoperative autoblood reservation (7-8 ml/kg)
Trial: 9672338
Drug: RBC 400
RxNorm normalized name: Ultratag RBC KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RBC 400 mg b.i.d. plus clarithromycin 500 mg b.i.d. (RBC-CLA)
Trial: 9672338
Drug: RBC 400
RxNorm normalized name: Ultratag RBC KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RBC 400 mg b.i.d. plus tetracycline 500 mg q.i.d. plus metronidazole 500 mg t.i.d. (RBC-TET-MET)
Trial: 9672338
Drug: RBC 400
RxNorm normalized name: Ultratag RBC KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RBC 400 mg b.i.d. plus amoxycillin 1000 mg b.i.d. plus clarithromycin 500 mg b.i.d. (RBC-AMO-CLA)
Trial: 9672338
Drug: 14-day RBC
RxNorm normalized name: Ultratag RBC KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 14-day RBC 400 mg b.i.d. plus clarithromycin 500 mg b.i.d. (RBC-CLA)
Trial: 7943693
Drug: Second dose
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Second dose of mivacurium after complete recovery from > 95% neuromuscular block
Trial: 7943693
Drug: Second dose
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Second dose of mivacurium after 100 s exclusion from peak effect
Trial: 31206749
Drug: Crestal implant
RxNorm normalized name: Crystal ammonia
DrugBank: Ammonium carbonate (DB15926)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Crestal implant placement (Group-A)
Trial: 31206749
Drug: Connective tissue
RxNorm normalized name: Connective tissue protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Connective tissue graft (CTG) over the implant neck (Group-B)
Trial: 20214062
Drug: Acupuncture treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture treatment with alternative use of two groups of acupoints and electroacupuncture in disperse-dense wave for 30 min
Trial: 7745071
Drug: 100 micrograms
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 micrograms gonadotrophin‐releasing hormone (GnRH)
Trial: 7745071
Drug: 500 micrograms
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 micrograms GnRH agonist (GnRHa)
Trial: 6118058
Drug: PGE‐2 aerosol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PGE‐2 aerosol in alcohol solution
Trial: 25526757
Drug: Intravaginal metronidazole
RxNorm normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravaginal metronidazole 750 mg plus miconazole 200 mg
Trial: 21046988
Drug: Livina (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Livina (2 capsules twice daily) with ATT
Trial: 17987463
Drug: Diluted diesel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diluted diesel exhaust (DE) inhalation (200 microg/m(3) of fine particulate matter)
Trial: 15955903
Drug: Cumulative dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cumulative dexamethasone dose
Trial: 8659761
Drug: Felodipine infusion
RxNorm normalized name: Felodipine
DrugBank: Felodipine (DB01023)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Felodipine infusion
Trial: 2223582
Drug: Tamoxifen (TM),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamoxifen (TM), 30 mg per day for 2 years
Trial: 7368968
Drug: Subcutaneous heparin,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous heparin, 5 000 IU twice daily
Trial: 30411542
Drug: Non-intensive education
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-intensive education format (sequential 90-min tutorials delivered 1 week apart)
Trial: 17326161
Drug: Sertraline (75-100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertraline (75-100 mg/day)
Trial: 11035676
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (FM plus BUD)
Trial: 11035676
Drug: All three
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All three treatments (FM, BUD, FM plus BUD)
Trial: 8736460
Drug: Pinacidil (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pinacidil (25 mg, orally)
Trial: 1302543
Drug: Cang Dou
RxNorm normalized name: Cang zhu
DrugBank: Atractylodes lancea root (DB14693)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cang Dou Pill
Trial: 3927691
Drug: Nicardipine (average
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicardipine (average daily dosage 89 mg, range 40 to 160)
Trial: 30606188
Drug: Opioid substitution
RxNorm normalized name: hydroxypropyl cellulose, low substituted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Opioid substitution treatment (OST)
Trial: 31655598
Drug: OSCAR intervention
RxNorm normalized name: OsCal 500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OSCAR intervention (monthly structured interviews by Social Care Nurses)
Trial: 20166794
Drug: Aripiprazole 10
RxNorm normalized name: aripiprazole 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aripiprazole 10 mg/day
Trial: 21823911
Drug: Aripiprazole 10
RxNorm normalized name: aripiprazole 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aripiprazole 10 mg/day and 30 mg/day pooled
Trial: 16719877
Drug: Midazolam (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam (0.5 mg x kg(‐1)) with diphenhydramine (1.25 mg x kg(‐1))
Trial: 16719877
Drug: Midazolam (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam (0.5 mg x kg(‐1)) alone
Trial: 15553109
Drug: Single oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral dose of 3 mg phenprocoumon
Trial: 28972854
Drug: 500 mL
RxNorm normalized name: TPN Bag 500 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mL of carbohydrate drink (CHO)
Trial: 26315481
Drug: Corticosteroid combined
RxNorm normalized name: combinations of corticosteroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticosteroid combined with oral tacrolimus (TAC, target trough blood concentration of 4‐8 ng/mL)
Trial: 26315481
Drug: Intravenous cyclophosphamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous cyclophosphamide (CYC, 750 mg/m(2)/mo)
Trial: 26315481
Drug: Oral mycophenolate
RxNorm normalized name: mycophenolate
DrugBank: Mycophenolic acid (DB01024)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral mycophenolate mofetil (MMF, 1.5‐2.0 g/d)
Trial: 1677320
Drug: 15 mg
RxNorm normalized name: papain 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg MK-467
Trial: 1677320
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg MK-467
Trial: 6869349
Drug: Metoclopramide 10
RxNorm normalized name: metoclopramide 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoclopramide 10 mg orally before meals and at bedtime
Trial: 6869349
Drug: Conventional endoscopic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional endoscopic treatment (mechanical fragmentation and instillation of papain solution)
Trial: 6869349
Drug: Long-term metoclopramide
RxNorm normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Long-term metoclopramide treatment
Trial: 31873985
Drug: Febuxostat (10‐40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Febuxostat (10‐40 mg)
Trial: 31873985
Drug: Allopurinol (100‐200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Allopurinol (100‐200 mg)
Trial: 27695944
Drug: Topical administration
RxNorm normalized name: Octocaine 5 % Ointment for Oral and Topical Administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical administration of 9 mg of sodium hyaluronate in 3 mL of a 0.9% sodium saline solution
Trial: 27695944
Drug: Normal 0.9%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal 0.9% sodium chloride saline solution
Trial: 25204290
Drug: Comprehensive therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comprehensive therapy based on traditional Chinese medicine (TCM) patterns including Bu‐Fei Jian‐Pi granules, Bu‐Fei Yi‐Shen granules, and Yi‐Qi Zi‐Shen granules along with conventional western medicine.
Trial: 26909960
Drug: Conventional western
RxNorm normalized name: western larch pollen extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional western medicine (control group).
Trial: 21756153
Drug: CsA +
RxNorm normalized name: CsA
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CsA + CBD ointment
Trial: 19617379
Drug: Magnesium sulphate
RxNorm normalized name: Magnesium sulphate
DrugBank: Magnesium (DB14513)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Magnesium sulphate 50 mg kg(‐1)
Trial: 18154123
Drug: Intraoperative bolus-assisted
RxNorm normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraoperative bolus-assisted administration of 5-fluorouracyl
Trial: 7800739
Drug: 0.7 mg
RxNorm normalized name: naloxone 0.7 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.7 mg nicotine cigarette
Trial: 7800739
Drug: 1.5 mg
RxNorm normalized name: boron 1.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 mg nicotine cigarette
Trial: 7800739
Drug: 0.1 mg
RxNorm normalized name: biotin 0.1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1 mg nicotine cigarette (control)
Trial: 7800739
Drug: All groups
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All groups (0.1 mg, 0.7 mg, 1.5 mg)
Trial: 7800739
Drug: 0.7 mg
RxNorm normalized name: naloxone 0.7 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.7 mg and 1.5 mg groups
Trial: 3142197
Drug: CQP 201-403
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CQP 201-403 (0.05 mg to 0.035 mg)
Trial: 3142197
Drug: CQP 201-403
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CQP 201-403 (0.025 mg)
Trial: 30977089
Drug: Chromium and
RxNorm normalized name: Cinnamon, Chromium and Biotin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chromium and carnitine co-supplementation (200 μg/day chromium picolinate plus 1000 mg/day carnitine)
Trial: 28535933
Drug: Oseltamivir +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oseltamivir + Azithromycin (500 mg/day for 5 days)
Trial: 18341664
Drug: Topical retapamulin
RxNorm normalized name: retapamulin Topical Ointment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical retapamulin ointment 1% twice daily for 5 days
Trial: 18341664
Drug: Topical retapamulin
RxNorm normalized name: retapamulin Topical Ointment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical retapamulin ointment 1%
Trial: 2874823
Drug: ICI 162,846
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ICI 162,846 0.5 mg
Trial: 2874823
Drug: ICI 162,846
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ICI 162,846 1.0 mg
Trial: 2874823
Drug: ICI 162,846
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ICI 162,846 2.5 mg
Trial: 2874823
Drug: ICI 162,846
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ICI 162,846 5.0 mg
Trial: 24721143
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of motivational and volitional strategies to promote walking
Trial: 23817284
Drug: MD.2 medication-dispensing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MD.2 medication-dispensing machine with care coordination
Trial: 20639023
Drug: Drug therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug therapy plus behavioral training (oxybutynin with pelvic floor muscle training and urge suppression techniques)
Trial: 20639023
Drug: Drug therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug therapy alone (oxybutynin)
Trial: 20639023
Drug: Drug therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug therapy plus behavioral training
Trial: 20143047
Drug: Drug therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug therapy alone
Trial: 18685512
Drug: Probiotics and
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotics and prebiotics treatment
Trial: 16618656
Drug: Topical decongestants
RxNorm normalized name: Qlearquil Nasal Decongestant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical decongestants (nafazoline and epinephrine)
Trial: 14583062
Drug: Chronomodulated infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chronomodulated infusion of oxaliplatin, fluorouracil and folinic acid
Trial: 14583062
Drug: Fixed-rate infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fixed-rate infusion of oxaliplatin, fluorouracil and folinic acid
Trial: 6084124
Drug: Hydrochlorothiazide (HCTZ),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide (HCTZ), 50 mg twice daily
Trial: 6084124
Drug: Guanabenz, 4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guanabenz, 4 to 32 mg twice daily
Trial: 30065939
Drug: LH‐RHa therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LH‐RHa therapy followed by a second orchidopexy
Trial: 26395174
Drug: OLM/AML 40/10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OLM/AML 40/10 mg
Trial: 24313633
Drug: Sertraline 50
RxNorm normalized name: sertraline 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertraline 50 mg daily for 8 weeks
Trial: 11399215
Drug: Individual cognitive-behavioral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individual cognitive-behavioral therapy
Trial: 116537
Drug: Intralipid infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intralipid infusion
Trial: 8124481
Drug: Insulin (control)
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin (control)
Trial: 2642566
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (not receiving immunotherapy)
Trial: 21464152
Drug: Traditional rapid
RxNorm normalized name: Abreva Rapid Pain Relief
DrugBank: Glycerin (DB09462)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional rapid palatal expansion and FM therapy
Trial: 17312278
Drug: Portal vein
RxNorm normalized name: Sus scrofa vein preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Portal vein embolization (PVE) + CD133(+) bone marrow stem cell (BMSC) administration
Trial: 17312278
Drug: Portal vein
RxNorm normalized name: Sus scrofa vein preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Portal vein embolization (PVE) + CD133(+) BMSC administration
Trial: 8997547
Drug: Nicergoline 30
RxNorm normalized name: nicergoline 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicergoline 30 mg b.i.d.
Trial: 7967862
Drug: Antibiotic prophylaxis
RxNorm normalized name: STONE PROPHYLAXIS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic prophylaxis (methronidazol and gentamicin, single preoperative dose)
Trial: 2442993
Drug: Indecainide (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indecainide (50 mg every 6 hours, increased to a maximum of 100 mg every 6 hours)
Trial: 2442993
Drug: Quinidine (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quinidine (200 mg every 6 hours, increased to a maximum of 400 mg every 6 hours)
Trial: 31539601
Drug: Cognitive Behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioral Stress Management Mobile Health application (CBSM mHealth) - 10 weekly modules
Trial: 15648985
Drug: Diclofenac 25
RxNorm normalized name: diclofenac 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diclofenac 25 mg
Trial: 14602746
Drug: Calcium (500
RxNorm normalized name: calcium gluconate 45 mg calcium (500 mg) ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium (500 mg) and vitamin D (400 IU) supplementation twice daily for 1 year
Trial: 10799375
Drug: 10 days
RxNorm normalized name: AlleRx 10-day Dose Pack
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 days of supplementation (1.67 MJ/d and 30 g protein/d)
Trial: 3145752
Drug: 120 mg
RxNorm normalized name: papain 120 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 120 mg terfenadine once daily
Trial: 17138832
Drug: Carbohydrate ingestion
RxNorm normalized name: pyrrolidone carboxylate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbohydrate ingestion (CHO) with 3 g/day L-carnitine
Trial: 17138832
Drug: Control (Con)
RxNorm normalized name: Afeditab CR
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Control (Con) with 3 g/day L-carnitine
Trial: 15855571
Drug: 5 microg
RxNorm normalized name: Digoxin 125 microgram oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 microg subcutaneous exenatide b.i.d.
Trial: 15855571
Drug: 10 microg
RxNorm normalized name: Estradiol 10 microgram vaginal tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 microg subcutaneous exenatide b.i.d.
Trial: 8313807
Drug: Intravenous amino
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous amino acids (Vamin 18, 250 mg protein/kg/hr) during normoglycemia
Trial: 8313807
Drug: Intravenous amino
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous amino acids (Vamin 18, 250 mg protein/kg/hr) during hyperglycemia